You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Discovery of new small molecule TLR4 agonists for the treatment of allergic rhinitis

    SBC: DiaCarta, Inc.            Topic: NIAID

    This pilot study is aimed at judging the efficacy of the lead compound with a clinically relevant allergenThe relevant allergen chosen for this study is the house dust mite Dermatophagoides pteronyssinus allergenDer pLoToxTM Natural Der pfrom Indoor Biotechnologies with a low endotoxin contentEUgWe are selecting this allergen because our team has extensive prior experience with this allergen in mo ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Acoustic Scaffold Bioreactor

    SBC: RESODYN CORPORATION            Topic: NHLBI

    This Small Business Innovation Research Phase II project will develop a commercially-viable device that uses micro-scale acoustic streaming (low frequency sound energy) to deliver mixing to the interior of three-dimensional (3D) scaffolds used for stem cell cultivation applications. The enabling advantage of low frequency sound energy is the ability to generate micro-scale mixing in and around sca ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Combinatorial Biomarkers for Malignant Polyps and Colon Cancer Detection

    SBC: Sanguine Diagnostics And Therapeutics, Inc.            Topic: 102

    ABSTRACT Technological advancements in colonoscopic and polypectomy procedures have drastically reduced both the incidence and overall mortality due to colorectal cancerCRCHowevereven with the availability of multiple screening toolsonlyof CRC are diagnosed at early stagein part due to lack of compliance with follow up colonoscopy procedurelimited access to colonoscopyThese factors contribute to i ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Discovery of NaV1.7 Inhibitors for the Treatment of Pain

    SBC: SITEONE THERAPEUTICS, INC.            Topic: 105

    PROJECT SUMMARY The objective of our program is to develop a safe and effective nonopioid analgesic for the treatment of neuropathic pain, such as pain associated with chemotherapy-induced peripheral neuropathy, that targets an isoform of the voltage-gated sodium ion channel, NaV1.7. Voltage-gated sodium channels are involved in the transmission of nociceptive signals from their site of origin in ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Adherence Monitor for Substance Use Disorder Treatment

    SBC: YELLOWSTONE SCIENTIFIC INSTRUMENTS            Topic: NIDA

    Project Summary The aim of the present SBIR program is to develop a new noninvasive, point-of-care testing device for patients undergoing treatment for substance use disorder. The new device will be capable of monitoring the progress and verifying patient adherence to prescribed treatment by detecting the presence and level of a compounded adherence marker released in the urine, providing for the ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Novel antibacterial agents derived from natural products

    SBC: Promiliad Biopharma Incorporated            Topic: NIAID

    SPECIFIC AIMSAntibiotic resistance among common bacterial pathogens is a serious public health problem as it compromises our ability to treat infectious disease. The resistance problem is compounded by the relative lack of discovery of new antibiotics, especially those with novel mechanisms of action. New antibiotics are critically needed as resistance to recently developed antibiotics is growing. ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Novel synthetic TLR4 agonists

    SBC: INIMMUNE CORP            Topic: NIAID

    Project SummaryThere are currently no approved vaccines for most emerging biological pathogens (Ebola, Chikungunya, MERS CoV, SARS, Zika), opportunistic infections (S. aureus, Candidiasis, adenovirus) or potential bioterrorism agents (Y. pestis, B. Pseudomallei, F. tularensis, Bunyaviridae, Flaviviridae), and therapeutic interventions such as antibiotics and antivirals are only effective for a sel ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Acoustic Enhanced Cell Culture

    SBC: RESODYN CORPORATION            Topic: 400

    This Small Business Innovation Research Phase I project will develop a prototype and then evaluate a novel device that utilizes low frequency sound energy to enhance cell culture productivityThe acoustic micromixing generated by the proposed device is compatible with cells and possesses the capability to substantially enhance the culture efficiency of cells cultured in typical culture vesselsThis ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Development of NaV1.7 Inhibitors for the Treatment of Chronic Cough

    SBC: SITEONE THERAPEUTICS, INC.            Topic: NHLBI

    PROJECT SUMMARYThe objective of our program is to develop a safe and effective therapeutic for chronic coughChronic coughor cough that persists for more than eight weeksis a condition that is often associated with diseases such as chronic obstructive pulmonary disorderCOPDasthmaidiopathic pulmonary fibrosisbronchiectasis or gastroesophageal reflux diseaseGERDIn other casesthe etiology is unknownCh ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  10. A robust assay for detecting agonist bias in living cells.

    SBC: MONTANA MOLECULAR LLC            Topic: 300

    ! Project Summary The objective of this SBIR Phase II project is to optimize and validate a prototype assay for ligand bias to be used in screening drugs that target seven transmembrane G- protein coupled receptors (GPCRs). The assay is based on genetically-encoded fluorescent biosensors that report signaling with a change in fluorescence intensity. Aim 1 of this project involves engineering and t ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government